SCHEMBL21158720

SCHEMBL21158720

CCN1CC2CC(C1)N2Cc1cnn(C(C)C)c1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RET P07949 2/20 0.40
PDE8B O95263 1/20 0.38
MAPT P10636 2/20 0.38
KMT2A Q03164 4/20 0.37
ALDH1A1 P00352 2/20 0.37
MEN1 O00255 2/20 0.37
ATM Q13315 1/20 0.37
ABL1 P00519 2/20 0.35
RIN1 Q13671 2/20 0.35
ALPL P05186 1/20 0.35
ALPI P09923 1/20 0.35
ALPG P10696 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
TLR9 Q9NR96 1/20 0.30
TLR8 Q9NR97 1/20 0.30
TLR7 Q9NYK1 1/20 0.30
PARG Q86W56 1/20 0.30
ACHE P22303 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20149624 0.86 RET (0.41) RETPDE8BMAPTKMT2AALDH1A1
SCHEMBL22031246 0.86 RET (0.41) RETPDE8BMAPTKMT2AALDH1A1
SCHEMBL20148684 0.83 RET (0.43) RETPDE8BMAPTKMT2AALDH1A1
SCHEMBL20071330 0.83 RET (0.39) RETPDE8BMAPTKMT2AALDH1A1
SCHEMBL20328915 0.77 MAPT (0.52) RETPDE8BMAPTKMT2AALDH1A1
SCHEMBL20071347 0.76 RET (0.39) RETMAPTKMT2AALDH1A1MEN1
SCHEMBL20149633 0.73 OPRM1 (0.39) RETALDH1A1
SCHEMBL12384827 0.70 KMT2A (0.47) RETPDE8BMAPTKMT2AALDH1A1
SCHEMBL22509567 0.70 L3MBTL1 (0.48) RETPDE8BMAPTKMT2AALDH1A1
SCHEMBL18713233 0.69 CHRNB2 (0.49) RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10555944-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ELI LILLY AND COMPANY (US) 2020-02-11 US disclosed
US-20190183886-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2019-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10555944-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF RET 1/4885PDE8B 511/4885MAPT 1769/4885
US-20190183886-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF RET 1/4885PDE8B 511/4885MAPT 1769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.